Soluble CD14 is subtype-dependent in serum but not in cerebrospinal fluid in people with HIV.
Cerebrospinal fluid
HIV-1
HIV-associated neurocognitive disorders
Soluble CD14
Subtypes
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 05 2022
15 05 2022
Historique:
received:
03
12
2021
revised:
20
01
2022
accepted:
08
03
2022
pubmed:
22
3
2022
medline:
12
4
2022
entrez:
21
3
2022
Statut:
ppublish
Résumé
Monocytes and macrophages activation are crucial in human immunodeficiency virus (HIV) central nervous system (CNS) infection and HIV associated neurocognitive disorders (HAND) pathogenesis. The soluble form of CD14 (sCD14) is a marker of monocyte activation. We hypothesized that sCD14 levels would be lower in people with HIV-1 subtype C (HIV-1C) than in HIV-1B owing to a variant Tat cysteine dimotif (C30S31) with reduced chemotactic activity. A total of 68 paired cerebrospinal fluid (CSF) and blood samples from people with HIV (PWH); 27 samples of the HIV-1B subtype and 40 of the non-B HIV-1 subtypes (including 26,HIV-1C), and 18 HIV-negative controls were included. sCD14 levels were quantified using a high-sensitivity enzyme-linked immunosorbent assay. sCD14 increase in serum, but not in CSF, was higher in samples from HIV-1B than HIV-1C (p = 0.002; Cohen's d, 0.7). CSF or serum sCD14 values were not correlated with global deficit score or specific cognitive domains. The impact of HIV-1 on monocyte stimulation biomarkers evaluated by sCD14 in serum was subtype-dependent, higher in HIV-1B than HIV-1C, consistent with reduced chemotactic activity as hypothesized.
Identifiants
pubmed: 35313166
pii: S0165-5728(22)00040-6
doi: 10.1016/j.jneuroim.2022.577845
pmc: PMC10373575
mid: NIHMS1913595
pii:
doi:
Substances chimiques
Biomarkers
0
Lipopolysaccharide Receptors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
577845Subventions
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062512
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH076651
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Références
J Neurovirol. 2019 Dec;25(6):837-843
pubmed: 31297727
Alzheimers Res Ther. 2017 Dec 15;9(1):98
pubmed: 29246249
J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):234-43
pubmed: 22569268
AIDS Res Hum Retroviruses. 2021 Sep;37(9):657-665
pubmed: 33472520
J Neurovirol. 2021 Feb;27(1):126-136
pubmed: 33462791
J Biol Chem. 1997 Sep 5;272(36):22385-8
pubmed: 9278385
J Biol Chem. 2010 Jun 11;285(24):18319-25
pubmed: 20378550
Neurobiol Dis. 2020 Mar;136:104701
pubmed: 31837421
J Neurovirol. 2015 Aug;21(4):439-48
pubmed: 25776526
Immunol Rev. 2013 Jul;254(1):102-13
pubmed: 23772617
FASEB J. 2002 Apr;16(6):546-54
pubmed: 11919157
J Infect Dis. 2001 Sep 15;184(6):699-706
pubmed: 11517430
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3117-21
pubmed: 9501225
J Neurovirol. 2013 Dec;19(6):550-6
pubmed: 24277437
J Immunol. 1999 Sep 1;163(5):2953-9
pubmed: 10453044
J Neurovirol. 2016 Dec;22(6):715-724
pubmed: 27400932
Neurology. 2007 Oct 30;69(18):1789-99
pubmed: 17914061
Clin Neuropsychol. 2004 May;18(2):234-48
pubmed: 15587671
Front Immunol. 2019 Jun 26;10:1435
pubmed: 31297114
AIDS. 2008 Oct 1;22(15):1993-2000
pubmed: 18753928
PLoS One. 2021 May 13;16(5):e0250987
pubmed: 33983973
Front Neurol. 2018 Sep 21;9:791
pubmed: 30298049
J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):371-9
pubmed: 21646912
J Neuroimmunol. 2021 Jun 15;355:577542
pubmed: 33845284
Biochem J. 1996 Jan 15;313 ( Pt 2):633-40
pubmed: 8573103
J Neurovirol. 2018 Feb;24(1):28-40
pubmed: 29063514
AIDS. 2015 Jul 31;29(12):1483-91
pubmed: 26244388
J Acquir Immune Defic Syndr. 2020 Aug 15;84(5):514-521
pubmed: 32692110
mBio. 2021 Mar 16;12(2):
pubmed: 33727362
J Virol. 1999 Jan;73(1):152-60
pubmed: 9847317
PLoS One. 2008 Jun 25;3(6):e2516
pubmed: 18575590
Mol Biol Evol. 2013 Dec;30(12):2725-9
pubmed: 24132122
J Cell Physiol. 2008 Jul;216(1):128-34
pubmed: 18247371
J Virol. 2004 Mar;78(5):2586-90
pubmed: 14963162
AIDS Res Hum Retroviruses. 2009 Jul;25(7):691-9
pubmed: 19621989
J Neurovirol. 2020 Apr;26(2):241-251
pubmed: 32002817
J Immunol. 2009 Jan 1;182(1):588-95
pubmed: 19109192
Trends Immunol. 2016 Feb;37(2):154-165
pubmed: 26775912
J Neuroimmune Pharmacol. 2013 Dec;8(5):1123-35
pubmed: 24101401
J Neuroimmunol. 2016 Dec 15;301:41-48
pubmed: 27836178
J Leukoc Biol. 2018 Apr;103(4):671-680
pubmed: 29377283
PCR Methods Appl. 1995 Apr;4(5):S202-16
pubmed: 7580909
J Neurosci Res. 1996 Aug 15;45(4):375-81
pubmed: 8872897
AIDS. 2015 Jun 19;29(10):1263-5
pubmed: 26035325
J Biol Chem. 1998 Jun 26;273(26):15895-900
pubmed: 9632634
J Acquir Immune Defic Syndr. 2022 May 1;90(1):106-114
pubmed: 35090158
J Acquir Immune Defic Syndr. 2020 Jun 1;84(2):196-202
pubmed: 32084055
J Virol. 2007 Jun;81(11):5919-28
pubmed: 17376903
J Neurovirol. 2020 Feb;26(1):3-13
pubmed: 31281948
AIDS. 2019 Dec 1;33(15):2363-2374
pubmed: 31764101
AIDS. 2014 Sep 24;28(15):2175-87
pubmed: 25144219
J Immunol. 2007 Jan 15;178(2):798-807
pubmed: 17202341